Original language | English (US) |
---|---|
Pages (from-to) | e514-e518 |
Journal | Haematologica |
Volume | 103 |
Issue number | 11 |
DOIs | |
State | Published - Oct 31 2018 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haematologica, Vol. 103, No. 11, 31.10.2018, p. e514-e518.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
AU - Ravandi, Farhad
AU - Ritchie, Ellen K.
AU - Sayar, Hamid
AU - Lancet, Jeffrey E.
AU - Craig, Michael D.
AU - Vey, Norbert
AU - Strickland, Stephen A.
AU - Schiller, Gary J.
AU - Jabbour, Elias
AU - Pigneux, Arnaud
AU - Horst, Heinz August
AU - Récher, Christian
AU - Klimek, Virginia M.
AU - Cortes, Jorge E.
AU - Carella, Angelo Michele
AU - Egyed, Miklos
AU - Krug, Utz
AU - Fox, Judith A.
AU - Craig, Adam R.
AU - Ward, Renee
AU - Smith, Jennifer A.
AU - Acton, Gary
AU - Kantarjian, Hagop M.
AU - Stuart, Robert K.
N1 - Funding Information: 1University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Indiana University Simon Cancer Center, Indianapolis, IN, USA; 4Moffitt Cancer Center, Tampa, FL, USA; 5West Virginia University, Morgantown, WV, USA; 6Institut Paoli-Calmettes and Aix-Marseille University, Marseille, France; 7Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; 8David Geffen School of Medicine at University of California, Los Angeles, CA, USA; 9Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, France; 10University Hospital Schleswig-Holstein, Kiel, Germany; 11Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse, France; 12Memorial Sloan-Kettering Cancer Center, New York, NY, USA;13IRCCS AOU San Martino-IST, Genova, Italy; 14Kaposi Mor Teaching Hospital, Kaposvar, Hungary; 15Universitätsklinikum Münster, Germany; 16Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA and 17Medical University of South Carolina, Charleston, SC, USA #Current address: Klinikum Leverkusen, Germany Funding: this study was funded by Sunesis Pharmaceuticals Inc. (South San Francisco, CA, USA). Medical writing assistance was provided by Rebecca D. Miles, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA) and Janis Leonoudakis, PhD of LeoGraphy, LLC (Pleasanton, CA, USA), and was funded by Sunesis Pharmaceuticals. Correspondence: fravandi@mdanderson.org doi:10.3324/haematol.2018.191361 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.
PY - 2018/10/31
Y1 - 2018/10/31
UR - http://www.scopus.com/inward/record.url?scp=85055851886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055851886&partnerID=8YFLogxK
U2 - 10.3324/haematol.2018.191361
DO - 10.3324/haematol.2018.191361
M3 - Letter
C2 - 29794146
AN - SCOPUS:85055851886
SN - 0390-6078
VL - 103
SP - e514-e518
JO - Haematologica
JF - Haematologica
IS - 11
ER -